Biocitech appoints new ceo

Jean-Francois Boussard becomes chief executive of French life science technology park on 1 April.

Biocitech appoints new ceo
Jean-Francois Boussard will become chief executive of Biocitech, the French life science technology park in Paris, on 1 April. He replaces Jacques Lhomel, who is retiring to pursue personal projects.

Boussard joins Biocitech after a biotechnology career in academia and industry. From 1994, after six years as patents, licensing and legal director in a financial holding company, he became an independent consultant in enterprise creation and technology transfer. In 1998, he founded and was ceo of Substrat, a consultancy specialising in enterprise creation and management, project management and technology transfer in the field of biotechnology.

Prior to Substrat, Boussard was a manager for pharmaceuticals and biotechnology at France's innovation agency, Anvar, from 1982-88. From 1979-82, he was a biologist at LERS Synthelabo after an earlier spell as a research scientist at the University of Metz.

"I am looking forward to putting my scientific, legal and financial know-how to use to continue the rapid development of the park," said Boussard.

Biocitech provides offices, laboratories and technical and scientific services.

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Pharmaceutical
A bullish time for biotech

A bullish time for biotech

Biotechnology has changed healthcare radically over the past decade and its impact on the pharmaceutical sector is growing. Susan Birks reports on the impact of the biotech boom
Pharmaceutical
OGT begins full IVDR transition for CytoCell FISH probe portfolio

OGT begins full IVDR transition for CytoCell FISH probe portfolio

OGT has launched two IVDR-certified prenatal FISH probe kits as it begins transitioning its full CytoCell portfolio ahead of the EU’s 2028 Class C deadline
Pharmaceutical
CellCarta adds Tempus to companion diagnostic commercialisation network

CellCarta adds Tempus to companion diagnostic commercialisation network

CellCarta has partnered with Tempus to expand its CDx Commercialization Lab Network, giving biopharma sponsors a route from companion diagnostic development and regulatory approval to commercial testing in US oncology practice
Manufacturing
Edwards cryogenic portfolio now available globally

Edwards cryogenic portfolio now available globally

Bringing cryogenic cooling and vacuum technologies together in one integrated portfolio for customers worldwide
Manufacturing
SCHOTT Pharma launches EVERIC lyo & amber vials for light-sensitive ADCs

SCHOTT Pharma launches EVERIC lyo & amber vials for light-sensitive ADCs

Featuring the well-known EVERIC® lyo coating, EVERIC® lyo & amber is designed for lyophilised, light-sensitive antibody-drug-conjugates (ADCs). It offers reliable light protection at the primary packaging level, already during the fill-and-finish process. EVERIC amber is the first specialty vial for highly light-sensitive medications that simultaneously meets regulatory light transmission requirements in the EU, the U.S., and Japan
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing
Portable gas detection in the pharmaceutical sector

Portable gas detection in the pharmaceutical sector

Gas safety is a critical consideration in the pharmaceutical sector. Hazardous gases and airborne contaminants are common by-products of manufacturing processes … and employers must control worker exposure in accordance with relevant legislation and industry standards
Manufacturing
New legal duties for QPs in decentralised manufacturing

New legal duties for QPs in decentralised manufacturing

In this clip, Dr. Peter Gough explains that QPs will be responsible for supervising decentralised activities, conducting regular audits, carrying out periodic on-site visits, confirming GMP compliance to regulatory authorities and notifying changes that may affect quality or safety
Subscribe now